Spinal muscular atrophy (SMA) is a rare disease, affecting one in every 10,000 births. It is a genetic disease, caused by mutations in the SMN1 gene (survival of motor neurons).

The function of the SMN protein, the one encoded by the gene, is to maintain the survival of motor neurons.

The loss of these neurons, responsible for transmitting nerve impulses from the brain to the muscles, leads to a progressive weakening of muscle tone. Patients have difficulty standing or sitting and walking. The weakening of the muscles responsible for lung ventilation leads to respiratory disorders.

There is another almost identical gene, SMN2, which can also produce SMN, although in small amounts, so that the survival of SMA patients depends on the degree of functionality of SMN2. In its most severe form – SMA type 1 – the level of SMN produced by SMN2 is minimal and patients usually die in infancy, before the age of two.

On February 19, The New England Journal of Medicine, one of the most prestigious medical journals, published an article reporting on the results of a prenatal treatment to correct SMA1. This was the case of a girl who, after amniocentesis, was diagnosed with SMA type 1 in the 32nd week of pregnancy.

The medical team responsible was led by Dr. Richard S. Finkel, from Saint Jude Children’s Hospital in Memphis, Tennessee. The treatment used risdiplam, a drug that modifies the processing of the mRNA produced by SMN2, thereby increasing the level of SMN produced.

Until now, risdiplam had been used after birth, but in this case the parents had lost another baby girl to SMA and suggested doctors to start treatment before delivery.

As some data suggested that risdiplam could cross the placenta, the drug was administered orally to the mother from the 32nd week of pregnancy until delivery, which occurred at 39 weeks.

After birth, it was found that risdiplam had indeed reached the girl during the fetal period and treatment was continued in the baby. The girl has reached an age of 30 months without showing symptoms of SMA.

After birth, some other anomalies were detected, such as slight vision defects and a heart murmur, which resolved satisfactorily. The journal Nature, in its News section reported this important advance in the treatment of a rare disease2.

Although, as Finkel warns in the article, results obtained with a single case cannot be generalized. It opens a door of hope for in utero treatment of this disease, the prenatal diagnosis of which often leads to induced abortion.

In fact, although legal abortion is very restrictive in Muslim countries, prenatal diagnosis of SMA type 1 is considered sufficient cause to allow it3.

Luis Franco

Member of the Spanish Royal Academy of Sciences

Member of the Bioethics Observatory

 

References:

  1. Finkel, R. S., Hughes, S. H., Parker, J. A., Citivello, M. et al. (2025) Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy. New England J. Med. doi: 10.1056/NEJMc2300802.
  2. Mallapaty, S. Rare Genetic Disorder Treated in Womb for the First Time. (2025) Nature 638:869. doi: 10.1038/d41586-025-00534-0.
  3. Sasongko, T. H., Salmi, A. R., Zilfalil, B. A., Albar, M. A. y Mohd Hussin. Z. A. (2010) Permissibility of prenatal diagnosis and abortion for fetuses with severe genetic disorder: type 1 spinal muscular atrophy. Ann. Saudi Med. 30:427-31. doi: 10.4103/0256-4947.72259.

Share This Story, Choose Your Platform!